PE20240918A1 - Formulacion que comprende ceralasertib - Google Patents
Formulacion que comprende ceralasertibInfo
- Publication number
- PE20240918A1 PE20240918A1 PE2023002688A PE2023002688A PE20240918A1 PE 20240918 A1 PE20240918 A1 PE 20240918A1 PE 2023002688 A PE2023002688 A PE 2023002688A PE 2023002688 A PE2023002688 A PE 2023002688A PE 20240918 A1 PE20240918 A1 PE 20240918A1
- Authority
- PE
- Peru
- Prior art keywords
- conjugate
- cancer
- dota
- targeting ligand
- somatostatin receptor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940121422 ceralasertib Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- DTTJKLNXNZAVSM-JYCIKRDWSA-N imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane Chemical compound C[C@@H]1COCCN1c1cc(nc(n1)-c1cncc2[nH]ccc12)C1(CC1)[S@](C)(=N)=O DTTJKLNXNZAVSM-JYCIKRDWSA-N 0.000 title 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 4
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 239000012217 radiopharmaceutical Substances 0.000 abstract 2
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 2
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 229940010982 dotatate Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a una composicion radiofarmaceutica liquida caracterizada porque comprende: (a) un conjugado, en donde el conjugado es 225Ac-DOTA-TATE o 25Ac-DOTA-TOC; (b) uno o mas agentes estabilizantes y (c) un vehiculo acuoso; en donde el conjugado comprende un ligando de direccionamiento, que se une a un receptor de somatostatina (SSR), un agente quelante metalico unido por enlace covalente al ligando de direccionamiento y un radionucleido 225Ac. Tambien se refiere a metodos para preparar dichas composiciones radiofarmaceuticas, que se formula para infusion IV y su uso para tratar el cancer positivo para el receptor de somatostatina (SSTR+), tales como cancer neuroendocrino, linfatico, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021081978 | 2021-03-22 | ||
| PCT/EP2022/057305 WO2022200251A1 (en) | 2021-03-22 | 2022-03-21 | Formulation comprising ceralasertib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240918A1 true PE20240918A1 (es) | 2024-04-30 |
Family
ID=81325577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002688A PE20240918A1 (es) | 2021-03-22 | 2022-03-21 | Formulacion que comprende ceralasertib |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240173261A1 (es) |
| EP (1) | EP4312993A1 (es) |
| JP (1) | JP2024511100A (es) |
| KR (1) | KR20230160323A (es) |
| CN (1) | CN116997328A (es) |
| AR (1) | AR125190A1 (es) |
| AU (1) | AU2022242632A1 (es) |
| BR (1) | BR112023019034A2 (es) |
| CA (1) | CA3213832A1 (es) |
| CL (1) | CL2023002777A1 (es) |
| CO (1) | CO2023013986A2 (es) |
| CR (1) | CR20230494A (es) |
| DO (1) | DOP2023000199A (es) |
| IL (1) | IL305977A (es) |
| MX (1) | MX2023011076A (es) |
| PE (1) | PE20240918A1 (es) |
| TW (1) | TW202304457A (es) |
| WO (1) | WO2022200251A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| WO2018153972A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| CN112043831A (zh) * | 2019-06-05 | 2020-12-08 | 正大天晴药业集团股份有限公司 | 用于联合治疗乳腺癌的喹啉类化合物 |
-
2022
- 2022-03-17 TW TW111109757A patent/TW202304457A/zh unknown
- 2022-03-21 CN CN202280021971.7A patent/CN116997328A/zh active Pending
- 2022-03-21 AU AU2022242632A patent/AU2022242632A1/en active Pending
- 2022-03-21 EP EP22717111.3A patent/EP4312993A1/en active Pending
- 2022-03-21 WO PCT/EP2022/057305 patent/WO2022200251A1/en active Application Filing
- 2022-03-21 PE PE2023002688A patent/PE20240918A1/es unknown
- 2022-03-21 IL IL305977A patent/IL305977A/en unknown
- 2022-03-21 US US18/552,014 patent/US20240173261A1/en active Pending
- 2022-03-21 MX MX2023011076A patent/MX2023011076A/es unknown
- 2022-03-21 KR KR1020237035911A patent/KR20230160323A/ko unknown
- 2022-03-21 CA CA3213832A patent/CA3213832A1/en active Pending
- 2022-03-21 BR BR112023019034A patent/BR112023019034A2/pt unknown
- 2022-03-21 CR CR20230494A patent/CR20230494A/es unknown
- 2022-03-21 JP JP2023558276A patent/JP2024511100A/ja active Pending
- 2022-03-22 AR ARP220100665A patent/AR125190A1/es unknown
-
2023
- 2023-09-19 DO DO2023000199A patent/DOP2023000199A/es unknown
- 2023-09-20 CL CL2023002777A patent/CL2023002777A1/es unknown
- 2023-10-20 CO CONC2023/0013986A patent/CO2023013986A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023013986A2 (es) | 2023-11-10 |
| CA3213832A1 (en) | 2022-09-29 |
| DOP2023000199A (es) | 2023-12-15 |
| MX2023011076A (es) | 2023-09-29 |
| TW202304457A (zh) | 2023-02-01 |
| CR20230494A (es) | 2023-12-07 |
| EP4312993A1 (en) | 2024-02-07 |
| CL2023002777A1 (es) | 2024-03-01 |
| WO2022200251A1 (en) | 2022-09-29 |
| KR20230160323A (ko) | 2023-11-23 |
| JP2024511100A (ja) | 2024-03-12 |
| IL305977A (en) | 2023-11-01 |
| AU2022242632A1 (en) | 2023-10-26 |
| BR112023019034A2 (pt) | 2023-10-17 |
| US20240173261A1 (en) | 2024-05-30 |
| AR125190A1 (es) | 2023-06-21 |
| CN116997328A (zh) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240917A1 (es) | Composiciones estabilizadas de radionucleidos y sus usos | |
| CO2017011536A2 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| BR112021002069A2 (pt) | Composição para tratamento capilar, métodos e usos da mesma. | |
| BR112016010927A2 (pt) | Conjugado de fórmula | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| BR112016011949A2 (pt) | Composto, composição farmacêutica, e, uso dos mesmos | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| AR081043A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
| UY37728A (es) | Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico | |
| AU2017250507A8 (en) | Methods of treatment using chlorotoxin conjugates | |
| BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
| BR112016029024A8 (pt) | composto, composição farmacêutica e uso | |
| ECSP18034035A (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico | |
| PE20181925A1 (es) | Composiciones antineoplasicas | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| UY38964A (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas | |
| MX2020003089A (es) | Analogos de tailanstatina. | |
| PE20240918A1 (es) | Formulacion que comprende ceralasertib | |
| CO2023001224A2 (es) | Métodos para mejorar la compatibilidad de formulaciones de protección de cultivos y aplicaciones de mezcla en tanque con fertilizantes líquidos | |
| BR112019024750A2 (pt) | uso de glutamina sintetase no tratamento da hiperamonemia |